Skip to main content

Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy.

Publication ,  Journal Article
Devi, GR; Finetti, P; Morse, MA; Lee, S; de Nonneville, A; Van Laere, S; Troy, J; Geradts, J; McCall, S; Bertucci, F
Published in: Cancers (Basel)
June 4, 2021

XIAP, the most potent inhibitor of cell death pathways, is linked to chemotherapy resistance and tumor aggressiveness. Currently, multiple XIAP-targeting agents are in clinical trials. However, the characterization of XIAP expression in relation to clinicopathological variables in large clinical series of breast cancer is lacking. We retrospectively analyzed non-metastatic, non-inflammatory, primary, invasive breast cancer samples for XIAP mRNA (n = 2341) and protein (n = 367) expression. XIAP expression was analyzed as a continuous value and correlated with clinicopathological variables. XIAP mRNA expression was heterogeneous across samples and significantly associated with younger patients' age (≤50 years), pathological ductal type, lower tumor grade, node-positive status, HR+/HER2- status, and PAM50 luminal B subtype. Higher XIAP expression was associated with shorter DFS in uni- and multivariate analyses in 909 informative patients. Very similar correlations were observed at the protein level. This prognostic impact was significant in the HR+/HER2- but not in the TN subtype. Finally, XIAP mRNA expression was associated with lower pCR rate to anthracycline-based neoadjuvant chemotherapy in both uni- and multivariate analyses in 1203 informative patients. Higher XIAP expression in invasive breast cancer is independently associated with poorer prognosis and resistance to chemotherapy, suggesting the potential therapeutic benefit of targeting XIAP.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

June 4, 2021

Volume

13

Issue

11

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Devi, G. R., Finetti, P., Morse, M. A., Lee, S., de Nonneville, A., Van Laere, S., … Bertucci, F. (2021). Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. Cancers (Basel), 13(11). https://doi.org/10.3390/cancers13112807
Devi, Gayathri R., Pascal Finetti, Michael A. Morse, Seayoung Lee, Alexandre de Nonneville, Steven Van Laere, Jesse Troy, Joseph Geradts, Shannon McCall, and Francois Bertucci. “Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy.Cancers (Basel) 13, no. 11 (June 4, 2021). https://doi.org/10.3390/cancers13112807.
Devi GR, Finetti P, Morse MA, Lee S, de Nonneville A, Van Laere S, et al. Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. Cancers (Basel). 2021 Jun 4;13(11).
Devi, Gayathri R., et al. “Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy.Cancers (Basel), vol. 13, no. 11, June 2021. Pubmed, doi:10.3390/cancers13112807.
Devi GR, Finetti P, Morse MA, Lee S, de Nonneville A, Van Laere S, Troy J, Geradts J, McCall S, Bertucci F. Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. Cancers (Basel). 2021 Jun 4;13(11).

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

June 4, 2021

Volume

13

Issue

11

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis